Benzomorphan Analogs for Opioid Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly for chronic pain, often lead to side effects such as constipation due to opioid analgesics and can result in analgesic tolerance, with existing compounds having limitations in receptor activity and biodistribution.
Innovation Solution
Development of novel benzomorphan analogs with specific receptor affinities, including agonist and antagonist activities at ORL-1, μ, δ, and κ opioid receptors, designed to provide effective analgesia with reduced side effects and improved biodistribution to mitigate constipation and tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are administered for pain management, then effective analgesia is achieved, but constipation and analgesic tolerance occur as side effects
Solution Approach 1:
The patent segments the opioid receptor system into multiple target receptors (μ, δ, κ, and ORL-1) and designs compounds that can selectively modulate each receptor type. By dividing the analgesic effect across multiple receptor mechanisms, the patent achieves reliable pain relief while reducing dependence on any single receptor pathway that causes constipation and tolerance
Solution Approach 2:
The benzomorphan analogs are designed to interact with multiple opioid receptor types (μ, δ, κ, and ORL-1) simultaneously, creating a multi-functional analgesic mechanism. This universal approach allows a single compound to provide comprehensive pain relief through diverse receptor pathways, thereby maintaining efficacy while mitigating side effects associated with single-receptor opioids
2Reliability
If existing opioid compounds are used, then pain relief is provided, but receptor activity limitations and poor biodistribution reduce therapeutic effectiveness
Solution Approach 1:
The patent systematically modifies chemical parameters of the benzomorphan core structure, including substitutions at positions 3, 6, 7, 8, 9, and 11 with various functional groups (halogens, alkyl chains, aryl groups, heterocycles). These parameter changes optimize receptor binding affinity across multiple opioid receptor types and improve biodistribution properties, enabling the compounds to overcome limitations of existing opioids
Solution Approach 2:
The benzomorphan analogs represent composite molecular structures combining the core benzomorphan framework with diverse substituent groups. This composite approach integrates multiple pharmacophoric elements within a single molecule, allowing simultaneous interaction with different opioid receptor subtypes and achieving versatile therapeutic effects that existing homogeneous opioid structures cannot provide
3Reliability
If high doses of opioids are administered to overcome tolerance, then analgesia is maintained, but respiratory depression risks increase
Solution Approach 1:
By segmenting the analgesic mechanism across multiple receptor types (μ, δ, κ, ORL-1), the patent reduces dependence on high-dose μ-receptor activation alone. The combined activity at multiple receptors provides additive or synergistic analgesic effects at lower overall doses, thereby maintaining pain relief while reducing respiratory depression risks associated with high-dose opioid therapy
Solution Approach 2:
The patent introduces ORL-1 receptor modulation as an intermediary mechanism that enhances analgesia through non-μ-receptor pathways. This intermediary approach provides alternative pain relief mechanisms that do not directly stimulate respiratory centers, allowing maintenance of analgesia while mitigating the respiratory depression that occurs with high-dose traditional opioid therapy
Data Source
AI summary
The invention provides compounds as represented by Formula I or I′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R1, R2, R2a, R3, and R4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and/or ORL-1 receptors.